Related references
Note: Only part of the references are listed.NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses
Yu-Cheng Lee et al.
CANCER CYTOPATHOLOGY (2022)
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian et al.
THYROID (2022)
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Francesca Negri et al.
ONCOLOGY REVIEWS (2021)
Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
Yan-Song Lin et al.
THYROID (2021)
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2021)
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Christelle de la Fouchardiere et al.
EUROPEAN JOURNAL OF CANCER (2021)
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update
Maciej Ratajczak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
HCC and Molecular Targeting Therapies: Back to the Future
Luca Rinaldi et al.
BIOMEDICINES (2021)
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
Mehtap Derya Aydemirli et al.
ENDOCRINE-RELATED CANCER (2021)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2021)
Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer
Viktoria Florentine Koehler et al.
THYROID (2021)
Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience
He-Jiun Jiang et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors - a single Brazilian center experience
Natalia Treistman et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2021)
Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
Sabih Jafri et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2021)
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
Hiroyuki Iwasaki et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
A Combinatorial Strategy for Targeting BRAFV600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
Chandrayee Ghosh et al.
CLINICAL CANCER RESEARCH (2020)
Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27
Hao Fu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
Timothy M. Ullmann et al.
SURGERY (2020)
Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
Bryan Haugen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas
Aswini Krishnan et al.
NATURE COMMUNICATIONS (2020)
Update on Fundamental Mechanisms of Thyroid Cancer
Alessandro Prete et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization
Ying-Hsia Chu et al.
MODERN PATHOLOGY (2020)
Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria
G. Rendl et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2020)
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A. Dunn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Janice M. Mehnert et al.
BMC CANCER (2019)
Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association
R. Michael Tuttle et al.
THYROID (2019)
Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma
Zhengshi Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer
Mihai Saftencu et al.
MEDICINA-LITHUANIA (2019)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Filetti et al.
ANNALS OF ONCOLOGY (2019)
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol
Amir Iravani et al.
THYROID (2019)
Evolving Understanding of the Epidemiology of Thyroid Cancer
Carolyn Dacey Seib et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Novel rearrangements involving the RET gene in papillary thyroid carcinoma
Julia Isabelle Staubitz et al.
CANCER GENETICS (2019)
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Laura Fugazzola et al.
EUROPEAN THYROID JOURNAL (2019)
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
Jierui Liu et al.
ENDOCRINOLOGY AND METABOLISM (2019)
Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo
Koji Tsumagari et al.
ENDOCRINE-RELATED CANCER (2018)
Current and future immunotherapies for thyroid cancer
Alessandro Antonelli et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna et al.
CLINICAL CANCER RESEARCH (2018)
Radioiodine refractory differentiated thyroid cancer
Yuchen Jin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
A Phase 2 Trial of Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Carcinoma in the First-Line Setting
M. S. Brose et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma
Thomas J. Giordano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
Tania Jaber et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Novel targeted therapies and immunotherapy for advanced thyroid cancers
George E. Naoum et al.
MOLECULAR CANCER (2018)
BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea
Mijin Kim et al.
THYROID (2018)
NCCN Guidelines® Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines
Robert I. Haddad et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)
J. Capdevila et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial
Tatiana C. Schneider et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Alain Ravaud et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of pazopanib in combination with escalating doses of 131 I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
Laura Q. Chow et al.
PLOS ONE (2017)
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
Lingxiao Cheng et al.
ONCOTARGET (2017)
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E
Zeus A. Antonello et al.
ONCOTARGET (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Irene M. Min et al.
CLINICAL CANCER RESEARCH (2017)
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer
Eric J. Sherman et al.
CANCER (2017)
Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer
Heqing Yi et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Manisha H. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society Consensus Statement AHNS Consensus Statement
Joseph Scharpf et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
Bruce Robinson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
CAR-T Cell Therapies From the Transfusion Medicine Perspective
Andrew Fesnak et al.
TRANSFUSION MEDICINE REVIEWS (2016)
Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid
Akira Miyauchi
WORLD JOURNAL OF SURGERY (2016)
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
Subrata Chowdhury et al.
ONCOTARGET (2016)
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma A Paradigm Shift to Reduce Overtreatment of Indolent Tumors
Yuri E. Nikiforov et al.
JAMA ONCOLOGY (2016)
A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
Maria E. Cabanillas et al.
CANCER (2015)
Targeted therapies in advanced differentiated thyroid cancer
Raquel M. Carneiro et al.
CANCER TREATMENT REVIEWS (2015)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study
D. Viola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: A Critical Review of the Risks and Benefits of Surgical Intervention Versus Active Surveillance
Ralph P. Tufano et al.
THYROID (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments
Laura D. Locati et al.
CANCER (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
Guidelines for the management of thyroid cancer
Petros Perros et al.
CLINICAL ENDOCRINOLOGY (2014)
Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
Ramona Dadu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
mTOR Inhibition Promotes TTF1-Dependent Redifferentiation and Restores Iodine Uptake in Thyroid Carcinoma Cell Lines
Theo S. Plantinga et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Jian Ma et al.
MOLECULAR CANCER (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Lise Boussemart et al.
NATURE (2014)
Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation
Yasuhiro Ito et al.
THYROID (2014)
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Martin Schlumberger et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
A Meta-analysis of the Effect of Prophylactic Central Compartment Neck Dissection on Locoregional Recurrence Rates in Patients with Papillary Thyroid Cancer
Tracy S. Wang et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Molecular Testing in Thyroid Cancer BRAF Mutation Status and Mortality
Anne R. Cappola et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
Daniel Chan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Systematic Review and Meta-Analysis of Prophylactic Central Neck Dissection on Short-Term Locoregional Recurrence in Papillary Thyroid Carcinoma After Total Thyroidectomy
Brian Hung-Hin Lang et al.
THYROID (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Effect of Prophylactic Central Compartment Neck Dissection on Serum Thyroglobulin and Recommendations for Adjuvant Radioactive Iodine in Patients with Differentiated Thyroid Cancer
Tracy S. Wang et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
D. Neil Hayes et al.
CLINICAL CANCER RESEARCH (2012)
Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells
Yu-Yu Liu et al.
ENDOCRINE-RELATED CANCER (2012)
The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
Ruixin Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux et al.
LANCET ONCOLOGY (2012)
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Ujjal Mallick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back
Byeong-Cheol Ahn
THERANOSTICS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin et al.
CLINICAL CANCER RESEARCH (2011)
Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer
F. Vaisman et al.
CLINICAL ENDOCRINOLOGY (2011)
OVERALL AND CAUSE-SPECIFIC SURVIVAL FOR PATIENTS UNDERGOING LOBECTOMY, NEAR-TOTAL, OR TOTAL THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER
Brandon M. Barney et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
The Surgical Management of Goiter: Part II. Surgical Treatment and Results
Gregory W. Randolph et al.
LARYNGOSCOPE (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Central Neck Dissection for Papillary Thyroid Cancer
David T. Hughes et al.
CANCER CONTROL (2011)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2010)
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus
Dingxie Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Does Postoperative Thyrotropin Suppression Therapy Truly Decrease Recurrence in Papillary Thyroid Carcinoma? A Randomized Controlled Trial
Iwao Sugitani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
MTOR downregulates iodide uptake in thyrocytes
Elaine Cristina Lima de Souza et al.
JOURNAL OF ENDOCRINOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes
Iwao Sugitani et al.
WORLD JOURNAL OF SURGERY (2010)
The β-Catenin Axis Integrates Multiple Signals Downstream from RET/Papillary Thyroid Carcinoma Leading to Cell Proliferation
Maria Domenica Castellone et al.
CANCER RESEARCH (2009)
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison
Robert F. Hobbs et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer
Electron Kebebew et al.
THYROID (2009)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper et al.
THYROID (2009)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells
Takahiko Kogai et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
R. Michael Tuttle et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer
Guido C. Hovens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Outcomes of patients with differentiated thyroid carcinoma following initial therapy
Jacqueline Jonklaas et al.
THYROID (2006)
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas:: Effects of the detection methods and genetic heterogeneity
Zhaowen Zhu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study
F Pacini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
RJ Robbins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
PAX8-PPAR gamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma
P Castro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Thyroid-hormone therapy and thyroid cancer: a reassessment
B Biondi et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2005)
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture
E Fröhlich et al.
ENDOCRINE-RELATED CANCER (2005)
Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines
JW Park et al.
THYROID (2005)
Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer
PI Haigh et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma
SM Coelho et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
BRAF mutations are associated with some histological types of papillary thyroid carcinoma
V Trovisco et al.
JOURNAL OF PATHOLOGY (2004)
BRAF mutations in an Italian cohort of thyroid cancers
L Fugazzola et al.
CLINICAL ENDOCRINOLOGY (2004)
Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population
KH Kim et al.
YONSEI MEDICAL JOURNAL (2004)
Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors
T Dwight et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
P Soares et al.
ONCOGENE (2003)
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
MN Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis
H Brenner
LANCET (2002)
PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma
TG Kroll et al.
SCIENCE (2000)
Share Paper
